公开(公告)号：US12090138B2

公开(公告)日：2024-09-17

申请号：US17588033

申请日：2022-01-28

Applicant: TASLY PHARMACEUTICAL GROUP CO., LTD.

Inventor： He Sun ,  Xijun Yan ,  Naifeng Wu ,  Kaijing Yan ,  Yonghong Zhu ,  Shunnan Zhang ,  Xiaolin Bai ,  Xiaohui Ma ,  Yi He ,  Ting Li ,  Lei Li

IPC: A61K31/357 ,  A61K9/08 ,  A61K9/16 ,  A61K9/48 ,  A61K31/205 ,  A61K31/355 ,  A61K31/683 ,  A61K36/488 ,  A61K36/82 ,  A61K47/24 ,  A61P1/16

CPC classification number: A61K31/357 ,  A61K9/08 ,  A61K9/1617 ,  A61K9/1682 ,  A61K9/48 ,  A61K31/205 ,  A61K31/355 ,  A61K31/683 ,  A61K36/488 ,  A61K36/82 ,  A61K47/24 ,  A61P1/16 ,  A61K2236/19

Abstract: A pharmaceutical composition is prepared from the following raw materials (in parts by weight): silybin (8.75-60), phospholipid (15-65), a Pu'er tea extract (25-200), and vitamin E (6.25-40). The composition has the effect of treating non-alcoholic fatty liver diseases.

公开(公告)号：US20240285568A1

公开(公告)日：2024-08-29

申请号：US18641536

申请日：2024-04-22

Applicant: William H. Cross, III

Inventor： William H. Cross, III

IPC: A61K31/198 ,  A61K31/145 ,  A61K31/205 ,  A61K31/4045 ,  A61K31/714 ,  A61P25/02

CPC classification number: A61K31/198 ,  A61K31/145 ,  A61K31/205 ,  A61K31/4045 ,  A61K31/714 ,  A61P25/02

Abstract: The invention provides compositions and methods to treat diabetic neuropathies. In particular, the invention provides combinations of at least two types of antioxidants have complementary effects for use against diabetic neuropathies. The two types of antioxidants include: antioxidants that comprise stabilizing heteroatoms and antioxidants with extended conjugated segments in a ring structure. At least one of each type of provided antioxidant has a pro-oxidative or conditionally pro-oxidative effect.

公开(公告)号：US11998577B2

公开(公告)日：2024-06-04

申请号：US17682051

申请日：2022-02-28

Applicant: ABBOTT LABORATORIES

Inventor： Alejandro Barranco Perez ,  Maria Ramirez Gonzalez ,  Rachael Buck ,  Enrique Vazquez Hernandez

IPC: A61K35/747 ,  A23L33/00 ,  A23L33/125 ,  A23L33/135 ,  A23L33/15 ,  A61K9/107 ,  A61K31/015 ,  A61K31/047 ,  A61K31/07 ,  A61K31/122 ,  A61K31/14 ,  A61K31/145 ,  A61K31/205 ,  A61K31/355 ,  A61K31/405 ,  A61K31/4188 ,  A61K31/4415 ,  A61K31/519 ,  A61K31/525 ,  A61K31/593 ,  A61K31/702 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  A61K31/714 ,  A61K33/06 ,  A61K33/26 ,  A61K33/30 ,  A61K35/20 ,  A61K35/745 ,  A61K47/02 ,  A61K47/12 ,  A61K47/14 ,  A61K47/22 ,  A61K47/24 ,  A61K47/26 ,  A61K47/36 ,  A61K47/42 ,  A61K47/44 ,  A61K47/46 ,  A61P1/14

CPC classification number: A61K35/747 ,  A23L33/125 ,  A23L33/135 ,  A23L33/15 ,  A23L33/40 ,  A61K9/107 ,  A61K31/015 ,  A61K31/047 ,  A61K31/07 ,  A61K31/122 ,  A61K31/14 ,  A61K31/145 ,  A61K31/205 ,  A61K31/355 ,  A61K31/405 ,  A61K31/4188 ,  A61K31/4415 ,  A61K31/519 ,  A61K31/525 ,  A61K31/593 ,  A61K31/702 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  A61K31/714 ,  A61K33/06 ,  A61K33/26 ,  A61K33/30 ,  A61K35/20 ,  A61K35/745 ,  A61K47/02 ,  A61K47/12 ,  A61K47/14 ,  A61K47/22 ,  A61K47/24 ,  A61K47/26 ,  A61K47/36 ,  A61K47/42 ,  A61K47/44 ,  A61K47/46 ,  A61P1/14 ,  A23V2002/00

Abstract: Disclosed are nutritional compositions including 2′-fucosyllactose (2′-FL) in combination with lutein and RRR-alpha-tocopherol. The nutritional compositions are useful for improving at least one of gut function, health, and development in an individual. In certain embodiments, the nutritional compositions can improve growth or maturation of the gut, as well as promote a healthy balance of beneficial bacteria in the gastrointestinal tract thereby treating and/or preventing formula intolerance or other gastrointestinal diseases and/or disorders resulting from suboptimal gastrointestinal flora population/balance.

公开(公告)号：US20240165149A1

公开(公告)日：2024-05-23

申请号：US18551781

申请日：2022-03-22

Applicant: OPHTALMIS

Inventor： Martine CLARET ,  Claude CLARET ,  Caroline CHATARD-BAPTISTE ,  Amir BONO

IPC: A61K31/733 ,  A61K31/205 ,  A61K31/37 ,  A61K31/525 ,  A61K31/593 ,  A61K33/30 ,  A61K36/73 ,  A61P1/00

CPC classification number: A61K31/733 ,  A61K31/205 ,  A61K31/37 ,  A61K31/525 ,  A61K31/593 ,  A61K33/30 ,  A61K36/73 ,  A61P1/00

Abstract: The present invention relates to a nutraceutical composition comprising inulin and a Chilean wineberry extract, and also other ingredients such as amino acids, vitamins and/or trace elements, in particular for the use thereof in preventing and/or treating ocular pathological conditions and/or in preventing and/or treating intestinal microbiota imbalances.

公开(公告)号：US20240165131A1

公开(公告)日：2024-05-23

申请号：US18426704

申请日：2024-01-30

Applicant: The Cleveland Clinic Foundation

Inventor： Stanley L. Hazen

IPC: A61K31/616 ,  A61K31/00 ,  A61K31/13 ,  A61K31/133 ,  A61K31/205 ,  A61K31/409 ,  A61K31/4164 ,  A61K31/43 ,  A61K31/4365 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/519 ,  A61K31/675 ,  A61K33/44 ,  A61P9/00 ,  A61P13/12 ,  G01N33/49

CPC classification number: A61K31/616 ,  A61K31/00 ,  A61K31/13 ,  A61K31/133 ,  A61K31/205 ,  A61K31/409 ,  A61K31/4164 ,  A61K31/43 ,  A61K31/4365 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/519 ,  A61K31/675 ,  A61K33/44 ,  A61P9/00 ,  A61P13/12 ,  G01N33/492 ,  G01N2800/32 ,  G01N2800/34 ,  G01N2800/52

Abstract: Provided herein are compositions, systems, and methods for treating a disease, such as kidney and/or cardiovascular disease, with an agent that reduces the production of trimethylamine (TMA) or trimethylamine-n-oxide (TMAO) in a subject. In certain embodiments, the agent is: i) 3,3-dimethyl-1-butanol (DMB) or a DMB derivative or related compound, ii) acetylsalicylic acid or derivative thereof (e.g., with an enteric coating for delivery to the colon and/or cecum); iii) a flavin monooxygenase 3 (FMO3) inhibitor; iv) a gut TMA lyase inhibitor; v) an antibiotic or antimicrobial; vi) a probiotic or prebiotic; vii) an antiplatelet agent; or viii) a TMA and/or TMAO sequestering agent.

公开(公告)号：US20240156732A1

公开(公告)日：2024-05-16

申请号：US17988570

申请日：2022-11-16

Applicant: Spartacus Brands LLC

Inventor： Augustin Quancard ,  Gregory Papigny ,  Jeremy Eisenberg ,  Stephanie Eisenberg

IPC: A61K9/127 ,  A61K31/205

CPC classification number: A61K9/127 ,  A61K31/205 ,  A61K9/0053

Abstract: A composition configured for oral consumption and formulated to improve the delivery of supplemental creatine is provided. The composition comprises supplemental creatine and a liposomal blend configured to encapsulate the supplemental creatine. Encapsulating the supplemental creatine with the liposomal blend improves the bioavailability of the supplemental creatine by protecting the supplemental creatine from degradation caused by the user's digestive system. The liposomal blend may further bind to the user's small intestine permitting the supplemental creatine to pass directly into the user's bloodstream, where it is accessible to the user's muscles.

公开(公告)号：US11957723B2

公开(公告)日：2024-04-16

申请号：US17947083

申请日：2022-09-16

Applicant: MarvelBiome, Inc.

Inventor： Jothi Amaranath Govindan ,  Elamparithi Jayamani ,  Priti H. Chatter ,  Mukesh Chatter

IPC: A61K35/747 ,  A61K31/132 ,  A61K31/19 ,  A61K31/194 ,  A61K31/198 ,  A61K31/205 ,  A61K31/405 ,  A61K31/4172 ,  A61K31/4402 ,  A61K31/455 ,  A61K31/522 ,  A61K31/575 ,  A61K35/741 ,  A61K35/742 ,  A61K35/745 ,  A61P25/28

CPC classification number: A61K35/747 ,  A61K31/132 ,  A61K31/19 ,  A61K31/194 ,  A61K31/198 ,  A61K31/205 ,  A61K31/405 ,  A61K31/4172 ,  A61K31/4402 ,  A61K31/455 ,  A61K31/522 ,  A61K31/575 ,  A61K35/741 ,  A61K35/742 ,  A61K35/745 ,  A61P25/28

Abstract: Methods and uses of compositions (e.g. comprising one or more microbial strains, one or more components, one or more metabolites, or a combination thereof) for treating neurodegenerative diseases, disorders, and conditions are disclosed.

公开(公告)号：US20240074894A1

公开(公告)日：2024-03-07

申请号：US18345638

申请日：2023-06-30

Applicant: Allergan, Inc.

Inventor： Sai Shankar

IPC: A61F9/00 ,  A61J1/14 ,  A61K31/205 ,  A61K31/407 ,  A61K31/496 ,  A61K31/498 ,  A61K31/5377 ,  A61K31/5575 ,  A61K31/573 ,  A61K38/13

CPC classification number: A61F9/0008 ,  A61J1/1475 ,  A61K31/205 ,  A61K31/407 ,  A61K31/496 ,  A61K31/498 ,  A61K31/5377 ,  A61K31/5575 ,  A61K31/573 ,  A61K38/13 ,  A61J1/18

Abstract: A container-closure system includes a container configured to hold a therapeutic liquid and having a dispensing tip configured to dispense a dose of the therapeutic liquid. A vented cap is configured to fit over at least a portion of the container including the dispensing tip and having one or more vents that allow air to pass into and out of a cavity defined between the vented cap and the dispensing tip. A second cap is configured to fit over at least a portion of the vented cap. A tamper evident seal is coupled to the second cap and one or both of the container and the vented cap.

公开(公告)号：US20240066001A1

公开(公告)日：2024-02-29

申请号：US18382997

申请日：2023-10-23

Applicant: Silti AG

Inventor： Gabriel GOJON-ZORRILLA ,  Gabriel GOJON-ROMANILLOS

IPC: A61K31/277 ,  A61K31/205 ,  A61K45/06

CPC classification number: A61K31/277 ,  A61K31/205 ,  A61K45/06

Abstract: The present invention relates to compositions and kits including a chemical uncoupler, such as tyrphostin 9 or precursor or a salt thereof, and compositions including a chemical uncoupler, such as tyrphostin 9 in combination with one or more therapeutic agents, for example, L-carnitine, which are useful, for example, in treating obesity, preventing weight gain, promoting weight loss/slimming, and/or treating or preventing the development of diabetes.

公开(公告)号：US20240058290A1

公开(公告)日：2024-02-22

申请号：US18268797

申请日：2021-12-19

Applicant: Hill's Pet Nutrition, Inc.

Inventor： Matthew JACKSON ,  Dennis JEWELL

IPC: A61K31/198 ,  A23K20/142 ,  A23K20/158 ,  A23K10/30 ,  A23K50/40 ,  A61K31/205 ,  A61K36/55 ,  A61K36/752 ,  A61K36/21 ,  A61K36/45 ,  A61P1/14

CPC classification number: A61K31/198 ,  A23K20/142 ,  A23K20/158 ,  A23K10/30 ,  A23K50/40 ,  A61K31/205 ,  A61K36/55 ,  A61K36/752 ,  A61K36/21 ,  A61K36/45 ,  A61P1/14

Abstract: Described herein are pet food compositions comprising an amino acid component comprising: lysine; betaine; and glutamic acid and/or a salt thereof present in an amount of about 7 wt. % or more, based on the total weight of the pet food composition; and about 3.3 wt. % or more, of a fatty acid component comprising a fatty acid having an aliphatic tail of 6 to 12 carbons and/or an omega-3 fatty acid, based on the total weight of the pet food composition.